TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20964568
Drug: Topical nitric
Normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitric oxide 3% plus cryotherapy
Study: 21186534
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV, 10 mg/d)
Study: 11982739
Drug: High-dose IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN-alpha induction therapy (6 MIU daily for 4 weeks and 3 MIU 3/7 days for 22 weeks)
Study: 11982739
Drug: Conventional IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IFN-alpha therapy (3 MIU 3/7 days for 26 weeks)
Study: 28721881
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (PORT) at 57.6 Gy or 63 Gy for lower-risk group; 63 Gy or 68.4 Gy for higher-risk group, all at 1.8 Gy per fraction.
Study: 26297187
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of albumin solution
Study: 23176678
Drug: Fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated milk (5 ppm fluoride, 200 ml daily)
Study: 23176678
Drug: Non-fluoridated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fluoridated milk (200 ml daily)
Study: 15451898
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection of the pylorus (200 units)
Study: 11165992
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment and prevention options for NSAID-associated ulcers
Study: 10890384
Drug: Interleukin-2 (IL2)
Normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL2) 5 million units/m2 once daily by constant intravenous infusion (CI) 5 days/week for 2 weeks
Study: 10890384
Drug: Interleukin-2 (IL2)
Normalized name: Interleukin-2 aldesleukin
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL2) 5 million units/m2 once daily by subcutaneous bolus (SB) injection 5 days/week for 2 weeks
Study: 30001745
Drug: Lotilaner (Credelio™)
Normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™) at 26 mg/kg (1×)
Study: 30001745
Drug: Lotilaner (Credelio™)
Normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™) at 78 mg/kg (3×)
Study: 30001745
Drug: Lotilaner (Credelio™)
Normalized name: lotilaner Chewable Tablet [Credelio]
DrugBank: Lotilaner (DB17992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™) at 130 mg/kg (5×)
Study: 27596059
Drug: 1-h plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h plasma glucose >8.6mmol/l (155mg/dl)
Study: 27596059
Drug: 1-h plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-h plasma glucose ≤8.6mmol/l (155mg/dl) and 2-h-PG <7.8mmol/l (140mg/dl)
Study: 19380175
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment (gemcitabine for a maximum of 6 cycles plus cetuximab until progression)
Study: 19380175
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (gemcitabine for a maximum of 6 cycles followed by cetuximab)
Study: 19380175
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment (CALC1-E)
Study: 9870121
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment (experimental group)
Study: 2233598
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg/day) + Acebutolol (200 mg/day)
Study: 2233598
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg/day) + Hydrochlorothiazide (25 mg/day)
Study: 24956095
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants with platform switching
Study: 16037143
Drug: ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.1 mg/kg IV)
Study: 12421239
Drug: Levofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (100 mg once a day) with Erythromycin (200 mg three times a day)
Study: 12421239
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg three times a day)
Study: 10696321
Drug: Topical 0.3%
Normalized name: triclosan topical 0.3% topical bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.3% ciprofloxacin
Study: 10696321
Drug: Topical 0.3%
Normalized name: triclosan topical 0.3% topical bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.3% ofloxacin
Study: 8698859
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion during euglycemia (day 1)
Study: 6213126
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of verapamil (single dose of 80 mg)
Study: 6213126
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of verapamil (single dose of 10 mg in 45 minutes)
Study: 26018599
Drug: ReCharge ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReCharge ice cream (100g for 2 weeks before and 6 weeks after chemotherapy)
Study: 26018599
Drug: ReCharge ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReCharge ice cream
Study: 24480604
Drug: Kangaroo holding
Normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo holding (1h of daily skin-to-skin contact on the chest of mother)
Study: 24480604
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no holding restrictions, received weekly brief social visits)
Study: 21540805
Drug: Methylprednisolone 40
Normalized name: methylprednisolone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 40 mg bolus injection
Study: 15528034
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1 g/d for a week)
Study: 9512083
Drug: HP 228
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 228 (30 microg/kg) plus Morphine (0.15 mg/kg)
Study: 8062152
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram of 1 alpha(OH)D3 daily
Study: 16214634
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral appliance
Study: 12360125
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n = 33)
Study: 9989538
Drug: Intravenous doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous doxycycline (100 mg every 12 hours)
Study: 9989538
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other antibiotic regimens)
Study: 2271433
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine
Study: 7246701
Drug: Neutral hypotonic
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral hypotonic tear preparations
Study: 25854932
Drug: Bushen Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Capsule (BSC), orally treated for 3 months
Study: 8021910
Drug: Nifedipine coat
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat core 30 mg once daily
Study: 8021910
Drug: Nifedipine coat
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat core 60 mg once daily
Study: 8021910
Drug: Nifedipine coat
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat core (both doses)
Study: 3415882
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with diazepam 0.14 mg kg‐1 by mouth
Study: 3415882
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with hyoscine 6 micrograms kg‐1 + morphine 0.2 mg kg‐1 i.m.
Study: 3415882
Drug: Lignocaine 1
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1 mg kg‐1 rapid i.v. injection
Study: 31667572
Drug: Trastuzumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab monotherapy (arm A)
Study: 31667572
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus mono-chemo-agent (arm B)
Study: 24843529
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 μg
Study: 21255526
Drug: Exenatide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (both doses)
Study: 19451281
Drug: Liposomal amikacin
Normalized name: amikacin liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal amikacin 500 mg by inhalation once daily for 14 days
Study: 11125606
Drug: Ketorolac administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac administered preoperatively (n = 25)
Study: 11125606
Drug: Ketorolac administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac administered at the conclusion of surgery (Control group, n = 24)
Study: 11125606
Drug: Total fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Total fentanyl use and postoperative oral analgesic requirements
Study: 9166164
Drug: Ampicillin-sulbactam for
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam for 72 hours followed by amoxicillin-clavulanate
Study: 9166164
Drug: Ampicillin for
Normalized name: Ampicillin for Injection
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin for 72 hours followed by amoxicillin
Study: 2892047
Drug: Calcium 500
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week
Study: 7502689
Drug: Calcium 500
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg/day
Study: 24081023
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg/week
Study: 25766052
Drug: Static hamstring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static hamstring stretching (4 exercises, 30 seconds each, performed twice with 15 seconds rest, 6 days per week for 7 weeks)
Study: 23622915
Drug: Essential medical
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential medical therapy before PCI
Study: 23622915
Drug: Essential medical
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential medical therapy at discharge after PCI
Study: 23622915
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use before PCI
Study: 23622915
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use after PCI
Study: 23622915
Drug: β-Blocker use
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-Blocker use before PCI
Study: 23622915
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy comparison based on history of myocardial infarction or revascularization before PCI
Study: 23622915
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy likelihood based on gender and dialysis status
Study: 20564933
Drug: Propofol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (4 mg/kg/hr) + Ketamine (2 mg/kg/hr)
Study: 20564933
Drug: Propofol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (4 mg/kg/hr) + Fentanyl (3 microg/kg/hr)
Study: 18230942
Drug: Structured Writing
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Writing Therapy (SWT)
Study: 26948519
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg)
Study: 18204981
Drug: alteplase infusion
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alteplase infusion plus weight-adjusted UH (24-48 h) and then enoxaparin (7 days)
Study: 11513446
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg three times a day, increased to 15 mg three times a day as needed)
Study: 11513446
Drug: Fluid therapy
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid therapy (increased fluid intake, salt tablets, and counseling)
Study: 7839092
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days
Study: 29768465
Drug: Truncated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truncated treatment (stopping antibiotics at Day 7)
Study: 29768465
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment (continuing antibiotics until Day 14)
Study: 29768465
Drug: Truncated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Truncated treatment
Study: 18826867
Drug: Different methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different methods for average bioequivalence evaluation including widening bioequivalence limits, scaling limits, and alternative bioavailability measures.
Study: 8574510
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195, 50 mg
Study: 8574510
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195, 100 mg
Study: 8574510
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195, 250 mg
Study: 8574510
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195, 500 mg
Study: 8574510
Drug: BAY x
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY x 7195, 1000 mg
Study: 11527144
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of bisoprolol once daily (o.d., n = 20)
Study: 11527144
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nifedipine sustained release (SR) b.i.d. (n = 20)
Study: 20938333
Drug: Oral pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral pregabalin 150 mg/12 h
Study: 20938333
Drug: Prazepam 10
Normalized name: prazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazepam 10 mg/12 h
Study: 12944569
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption for four months followed by a change in antiretroviral regimen
Study: 12944569
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption
Study: 12944569
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruption and immediate change in regimen
Study: 10658043
Drug: Acetazolamide (Acz;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (Acz; 10 mg/kg body wt iv)
Study: 8436155
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg orally three times a day
Study: 28898530
Drug: Intradiscal electrothermal
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal electrothermal therapy (IDET)
Study: 22411483
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 μg and Midazolam 7.5 mg
Study: 20973267
Drug: Canfosfamide +
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Canfosfamide + PLD (1000 mg/m² canfosfamide and 50 mg/m² PLD)
Study: 20973267
Drug: PLD alone
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD alone (50 mg/m²)
Study: 15809515
Drug: Chronic hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chronic hydrocortisone treatment (40 mg daily for 1 week)
Study: 15809515
Drug: Acute hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Acute hydrocortisone treatment (40 mg)
Study: 8512477
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone sodium succinate (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Study: 1734247
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral for 14 days)
Study: 31106353
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of systemic, pathogen-targeted antibiotic therapy
Study: 31106353
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of systemic, pathogen-targeted antibiotic therapy
Study: 24009749
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lutein supplement
Study: 21114552
Drug: Weekly e-mail
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly e-mail messages and monthly personal e-mail messages with reporting of weight (n = 28)
Study: 11412291
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg kg(‐1)
Study: 11412291
Drug: Propofol 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3.0 mg kg(‐1)
Study: 9764960
Drug: Formulation I
Normalized name: Recombivax HB, Hepatitis B Vaccine (Recombinant) Pediatric/Adolescent Formulation Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation I
Study: 9764960
Drug: Formulation II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation II
Study: 9764960
Drug: Formulation III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation III
Study: 9725476
Drug: Reference capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference capsule
Study: 8001064
Drug: 0.42% F
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42% F gel once a day for 1 year
Study: 8001064
Drug: 1.23% F
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% F gel for 4 weeks followed by 0.42% F gel daily for 1 year
Study: 8001064
Drug: Unstimulated saliva
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstimulated saliva flow < 0.1 ml/min
Study: 8001064
Drug: Stimulated salivary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated salivary flow < 0.5 ml/min
Study: 8001064
Drug: Unstimulated saliva
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstimulated saliva flow > 0.1 ml/min with 0.42% F gel
Study: 3356120
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg administered after a fast (Treatment A)
Study: 3356120
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg with a standardized high-fat meal (Treatment B)
Study: 3356120
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg with a standardized high-carbohydrate meal (Treatment C)
Study: 3356120
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg after pretreatment with glutamic acid hydrochloride 680 mg (Treatment D)
Study: 3356120
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg in a simulated achlorhydric state (Treatment E)
Study: 3356120
Drug: ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole 200 mg with glutamic acid hydrochloride in a simulated achlorhydric state (Treatment F)
Study: 14769704
Drug: Roxithromycin therapy
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin therapy for 30 days
Study: 14769704
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic therapy (control group)
Study: 11290877
Drug: Lanepitant 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant 50 mg daily
Study: 11290877
Drug: Lanepitant 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant 100 mg daily
Study: 11290877
Drug: Lanepitant 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant 200 mg twice daily
Study: 7803735
Drug: High-dose vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vecuronium (VEC) 400 micrograms/kg
Study: 7803735
Drug: High-dose vecuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vecuronium (VEC)
Study: 7803735
Drug: Doxacurium (DOX)
Normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxacurium (DOX) and High-dose vecuronium (VEC)
Study: 2904371
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sublingual tablet formulation of temazepam